tiprankstipranks
Advertisement
Advertisement

DNTH Stock Latest News

Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market
Company AnnouncementsDianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market
14d ago
DNTH
Dianthus initiates EMERGE trial of claseprubart
PremiumThe Fly
Dianthus initiates EMERGE trial of claseprubart
24d ago
DNTH
Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
PremiumThe Fly
Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
1M ago
SNY
DNTH
Dianthus reports additional data from Part A of CAPTIVITY study
PremiumThe Fly
Dianthus reports additional data from Part A of CAPTIVITY study
1M ago
DNTH
Dianthus rises 7.7%
PremiumThe Fly
Dianthus rises 7.7%
1M ago
DNTH
Dianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
PremiumCompany AnnouncementsDianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
1M ago
8K
DNTH
Dianthus price target raised to $132 from $110 at Jefferies
Premium
The Fly
Dianthus price target raised to $132 from $110 at Jefferies
1M ago
SNY
DNTH
Midday Fly By: SpaceX IPO oversubscribed, Chewy reports in-line Q1
Premium
The Fly
Midday Fly By: SpaceX IPO oversubscribed, Chewy reports in-line Q1
1M ago
F
SN
Dianthus falls -16.0%
PremiumThe Fly
Dianthus falls -16.0%
1M ago
DNTH
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
PremiumRatings
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
1M ago
DNTH
Dianthus falls -13.7%
PremiumThe Fly
Dianthus falls -13.7%
1M ago
DNTH
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
PremiumRatings
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
1M ago
DNTH
Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
PremiumThe FlyBuy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
1M ago
SNY
DNTH
Video: Cracker Barrel advances after beat and raise report
Premium
The Fly
Video: Cracker Barrel advances after beat and raise report
1M ago
SNY
CBRL
Morning Movers: Dianthus plummets after peer Sanofi halts trial
Premium
The Fly
Morning Movers: Dianthus plummets after peer Sanofi halts trial
1M ago
YB
CNM
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
PremiumThe Fly
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
1M ago
SNY
DNTH
Dianthus sinks after Sanofi halts CIDP Phase 3 study
PremiumThe Fly
Dianthus sinks after Sanofi halts CIDP Phase 3 study
1M ago
SNY
DNTH
Dianthus Therapeutics Stockholders Reaffirm Board and Governance Structure
PremiumCompany Announcements
Dianthus Therapeutics Stockholders Reaffirm Board and Governance Structure
2M ago
8K
DNTH
Dianthus price target lowered to $120 from $122 at Evercore ISI
PremiumThe Fly
Dianthus price target lowered to $120 from $122 at Evercore ISI
2M ago
DNTH
Dianthus price target raised to $125 from $123 at Raymond James
PremiumThe FlyDianthus price target raised to $125 from $123 at Raymond James
3M ago
DNTH
Dianthus reports Q1 EPS (85c), consensus ($1.10)
Premium
The Fly
Dianthus reports Q1 EPS (85c), consensus ($1.10)
3M ago
DNTH
Dianthus treatment of myasthenia gravis gets orphan status
Premium
The Fly
Dianthus treatment of myasthenia gravis gets orphan status
3M ago
DNTH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >